Please provide your email address to receive an email when new articles are posted on . The Merlin test, a clinical-pathologic and gene expression profile, was able to successfully classify 37% of ...
New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
The study assessed the overall diagnostic accuracy of the Merlin CP-GEP Test for predicting sentinel node metastases and recurrence risk The Merlin CP-GEP Test demonstrated strong predictive and ...
SkylineDx said its Merlin CP-GEP molecular test identifies a subset of T1a melanoma patients with sentinel lymph node (SLN) positivity above guideline thresholds. The National Comprehensive Cancer ...
ROTTERDAM, Netherlands and SAN DIEGO, Calif., Dec. 18, 2025 /PRNewswire/ -- SkylineDx today announced the release of new data from two complementary, peer-reviewed publications that reinforce the ...
The Merlin CP-GEP Test, validated in the largest prospective gene expression profiling study in melanoma (MERLIN_001), demonstrated that a High-Risk result identifies patients with a threefold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results